^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + nemvaleukin alfa (ALKS 4230) (IL-2R agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer
Published date:
10/25/2021
Excerpt:
Alkermes plc...today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, in combination with pembrolizumab, an anti-PD-1 antibody, for the treatment of platinum-resistant ovarian cancer.
